In this Mendelian randomization study, higher odds of developing heart failure were seen in regular vs never smokers and in current vs former smokers.
A higher risk for developing heart failure was recently linked to regular and current smokers compared with never and former smokers, according to findings presented in ESC Heart Failure.
Particularly, a genetic predisposition to smoking and a higher lifetime smoking burden increased the odds of developing the disease. Smoking burden was defined as length of time having smoked and cigarettes smoked per day. The authors investigated the likelihood of heart failure as it related to 3 smoking statuses (ever smoking, lifelong smoking duration, smoking cessation) and 4 smoking phenotypes (smoking initiation, age at initiation of regular smoking, cigarettes per day, smoking cessation). This is an area that requires exploration, they noted.
“Cigarette smoking has been associated with a higher risk of heart failure throughout observational studies,” the authors stated. “However, whether the total smoking burden and smoking cessation have causal effects on heart failure risk requires further exploration.”
Overall, the individuals (n = 47,309 with heart failure; n = 930,014 controls) were included in this analysis, and among them, higher odds ratios (ORs) were seen among ever regular smokers vs never smokers and current smokers vs former smokers for developing heart failure:
Similar results were seen when accounting for a genetic liability to smoking more cigarettes daily (OR, 1.37; 95% CI, 1.20-1.58; P = 6.4 × 10-6) and having a higher composite lifetime smoking index (OR, 1.49; 95% CI, 1.31-1.70; P = 2.5 x 10-9).
No link was found between the genetically predicted age at initiation of regular smoking and heart failure (OR, 0.71; 95% CI, 0.48-1.06; P = .10), but a positive correlation was seen for every 1 SD increase (ie, for current smokers, 8 cigarettes/day) in genetically instrumented cigarettes per day and risk of heart failure (OR, 1.37; 95% CI, 1.20-1.58; P = 6.4 × 10-6). Also, a 49% greater risk was seen when considering lifetime smoking index (OR, 1.49; 95% CI, 1.31-1.70; P = 2.5 × 10-9).
For this Mendelian randomization (MR) study, the authors extracted genetic variant data linked to smoking from the GWAS and Sequencing Consortium of Alcohol and Nicotine Use, a composite lifetime smoking index was derived from the UK Biobank, and the Heart Failure Molecular Epidemiology for Therapeutic Targets Consortium provided the associations between smoking phenotype and heart failure. MR, the authors pointed out, “is a genetic epidemiological method to explore the causal effect of an exposure on disease outcome, using genetic variants as instrumental variables.”
The associations they saw remained even after adjusting, individually and collectively, for body mass index, type 2 diabetes, lipid levels, and blood pressure—all known heart failure risk factors.
“This MR study indicated that genetic predisposition to ever smoking and to a higher lifetime smoking burden is associated with a higher risk of heart failure,” the authors conclude. “Our findings point to a potentially causal role of smoking in the pathogenesis of heart failure and highlight the importance of smoking cessation strategies to decrease the risk of heart failure.”
The inability of the investigators to evaluate associations between different regular smoking durations and smoking cessation with heart failure, the possibility of smoking’s impact being mediated by other disease pathways, and that most of the study participants were of European ancestry introduced limitations on the generalizability of these findings.
Reference
Lu Y, Xu Z, Georgakis MK, Wang Z, Lin H, Zheng L. Smoking and heart failure: a Mendelian randomization and mediation analysis. ESC Heart Fail. Published online March 3, 2021. doi: 10.1002/ehf2.13248
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Strategies Needed to Address Physical Activity Before, After CVD Events
August 1st 2025Black women had lower moderate-to-vigorous intensity physical activity scores when compared with Black and White men and their White female counterparts, highlighting the need for support across patient subgroups.
Read More
AI-Enhanced ECG Expands Access, Reduces Costs for Patients
July 25th 2025An AI model significantly outperformed cardiologists when reviewing ECGs of structural heart disease and may potentially be a step towards increased access and lower costs for early detection of conditions like heart failure and valvular heart disease.
Read More